Want to join the conversation?
$CELG's second pivotal trial CD-003 will initiate in a staggered parallel fashion early in 2016 and completion timing is similar to that of CD-002. The endoscopy study CD-001 is actively enrolling and the company expects to complete enrollment by year-end 2015. This study has an off-drug observation period up to 52 weeks.
$EXTR has been on an interesting uptrend, fundamentals kinda tricky but solid technical. Earnings 5th
Wow! $MCD scores again.